Sign up for important Repatha® updates


Considering Repatha®? Want to get in touch with a Rep? Need practice information? Sign up today to stay connected.

First Name

Enter first name

Last Name

Enter last name

Email

Enter email address

Zip Code

Enter zip code

I am a...

Select your title

Privacy Statement
By clicking "Submit," you agree to disclose your personal information to Amgen and to be contacted by Amgen and their agents in the future regarding products, services, and/or information related to Repatha®. For more information about Amgen's privacy practices, please visit www.amgen.com/privacy.


Submit

Thank you.


Okay

COVERAGE INFORMATION

Your patients count on you. You can count on us

Now, more than 80%* of patients pay less than $50 per month1


83% of patients pay less than $50

Discover the Repatha® Copay Card


96% of patients pay less than $50 with most patients paying less than $10



60% of patients will pay less than $50

Learn about the LIS "Extra Help" program below


*Based on average patient cost of Repatha® from 2019 commercial and Medicaid approved claims and 2020 Medicare formulary status.

Percentage is based upon claims data including those where copay card was used.

Patient out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit they are currently in. Medicare Part D drug coverage is divided into 4 phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.



Need help with Repatha® access for your patients?


A virtual Repatha® Access Specialist (RAS) who understands coverage in your region is available when you need assistance.

Contact your Virtual RAS for questions about access topics such as:

  • Understanding a payer’s coverage eligibility criteria
  • Navigating the PA process and/or appeals
  • Finding the correct form to use

For Virtual RAS support,
Call 1-844-889-9222
Monday through Friday,
8AM to 8PM ET.



Virtual RAS Information Card


Download



Access Repatha® coverage information, prior authorization (PA) requirements, health plan PA forms, and more.



Repatha® Copay Card reduces costs for Repatha® for eligible patients.


Learn more

CoverMyMeds: Offers electronic prior authorization submission


CoverMyMeds® electronically connects providers, pharmacists, and health plans


  • Offers a process for submitting electronic prior authorizations (ePAs) for Repatha®
  • Live chat and phone support available
  • The ability to attach documentation if required

Visit CoverMyMeds to learn more.



CoverMyMeds Brochure


Learn more details about the CoverMyMeds Program in this brochure


Download


Full LIS Medicare patients pay no more than $8.95 per Repatha® prescription


The LIS program, also known as “Extra Help,” limits prescription out-of-pocket costs for eligible Medicare Part D patients with limited income and resource limits.

Learn more about LIS or call 1-844-REPATHA.



Safety Net Foundation


Serving patients in need™

The Amgen Safety Net Foundation (ASNF) helps patients with financial need gain access to Amgen medicines at no cost.

Click here to see if your patient is eligible.

LIS=low-income subsidy.

Reference: 1. Data on file, Amgen; 2020.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.